Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

Ahead of World Diabetes Day, Doctors Without Borders (MSF) called on pharmaceutical corporations Eli Lilly, Novo Nordisk, ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

CINCINNNATI – Since the start of summer, officers at the port of Cincinnati have seized several unapproved shipments of the ...

U.S. Customs and Border Protection (CBP) officers at the port of Cincinnati have seized more unapproved shipments of ...

U.S. Customs and Border Protection officers in Cincinnati recently seized more shipments containing unapproved medications.